# Tesamorelin and rising IGF-1

> Tesamorelin in Peptide Clinical Evidence Journal — Peptide Clinical Evidence Journal examines tesamorelin’s rise in IGF-1, fat measurements in HIV-associated lipodystrophy and the limits of reassurance.

The hormone increase belongs in the conversation about fat reduction. For me, rising IGF-1 complicates the shrinking fat measurement.

## The hormone measurement

In [13 healthy men studied for two weeks](https://pubmed.ncbi.nlm.nih.gov/20943777/), tesamorelin increased mean overnight growth hormone and raised IGF-1 by 181 micrograms per litre. Fasting glucose and insulin-stimulated glucose uptake showed no statistically significant change. The brief experiment showed a hormonal response under observation.

IGF-1 is produced by the liver after growth-hormone stimulation. Tesamorelin prompts the pituitary gland to release the body’s own growth hormone in pulses. I prefer the endocrine starting point: a description focused only on fat loss can make the hormone change seem incidental. It is central to how the treatment works.

The short study supplies little reassurance about years of raised growth-factor exposure. Cancer risk over the long term remains a question alongside these changes. The absence of a clear glucose effect in this small, brief study also leaves plenty of room for uncertainty in people with different health conditions.

## HIV lipodystrophy trials

Tesamorelin’s [United States approval in 2010](https://www.ncbi.nlm.nih.gov/books/NBK548730/) concerns reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, an abnormal distribution of body fat. That specific indication determines the scope of the clinical story.

The [2026 meta-analysis of five randomized trials](https://pubmed.ncbi.nlm.nih.gov/41545261/) found reductions in visceral fat, trunk fat and liver fat, with an increase in lean body mass. Visceral fat surrounds abdominal organs; lean mass includes muscle and other nonfat tissue. The population was adults with HIV-associated lipodystrophy.

A [six-month trial in 50 adults receiving antiretroviral treatment](https://pubmed.ncbi.nlm.nih.gov/25038357/) found a treatment effect of −42 square centimetres in visceral-fat area and a reduction in liver fat. An area on a scan and a body weight answer different questions. I value the anatomical measurement, while resisting the leap to a general belly-fat treatment for people without HIV.

![A technician positions the scanning arm above an empty body-composition scanning table](images/body-composition-room.webp)

*Editorial illustration of a body-composition scanning room. The empty table emphasizes measurement, without depicting a study participant.*

## Continuing and stopping

In the [52-week program](https://pubmed.ncbi.nlm.nih.gov/18690162/), 273 people were assigned to tesamorelin and 137 to placebo. Continued treatment sustained visceral-fat reduction at 18% below baseline; visceral fat reaccumulated after treatment stopped. Overall changes in glucose parameters were not clinically significant over that period.

The return of fat is consequential. It makes the benefit dependent on time and continued exposure, which brings the hormonal safety questions back into the picture. A favorable scan at the end of treatment gives only one part of that account.

I regard ordinary weight gain, longevity and fewer cardiovascular events as questions beyond these trials. The study population and measurements are already specific enough to be useful.

## Liver injury and endocrine safety

The [LiverTox monograph](https://www.ncbi.nlm.nih.gov/books/NBK548730/) found no reported cases of clinically apparent liver injury attributable to tesamorelin and judged it an unlikely cause. That is a reassuring conclusion about a particular form of harm.

The growth-hormone and IGF-1 effects leave a broader safety discussion open, including glucose handling and long-term cancer concerns. The trials here followed defined groups for limited periods. Tesamorelin’s approved indication does not cover general weight loss or anti-aging use, and the existing sources also describe its prohibition in sport.

The observation I trust most is specific: reduced visceral fat during treatment in the studied HIV population. The [lab report index](/compare) places that result beside the other compounds without pretending they were tested for the same job.

---

Peptide Clinical Evidence Journal independently examines where metabolic biomarkers align with clinical outcomes; it is neither a clinic nor a vendor and does not provide medical advice.